Citation: Ran Xiao, Shan Li, Qian Cao, Xiuling Wang, Qiujin Yan, Xiaoning Tu, Ying Zhu, Fan Zhu. Human endogenous retrovirus W env increases nitric oxide production and enhances the migration ability of microglia by regulating the expression of inducible nitric oxide synthase .VIROLOGICA SINICA, 2017, 32(3) : 216-225.

Human endogenous retrovirus W env increases nitric oxide production and enhances the migration ability of microglia by regulating the expression of inducible nitric oxide synthase

HERV-W env increases NO and enhances migration of microglia

  • Corresponding author: Fan Zhu,, ORCID: 0000-0001-7031-2956
  • Received Date: 13 April 2017
    Accepted Date: 26 May 2017
    Published Date: 23 June 2017
    Available online: 01 June 2017
  • Human endogenous retrovirus W env (HERV-W env) plays a critical role in many neuropsychological diseases such as schizophrenia and multiple sclerosis (MS).These diseases are accompanied by immunological reactions in the central nervous system (CNS).Microglia are important immunocytes in brain inflammation that can produce a gasotransmitter-nitric oxide (NO).NO not only plays a role in the function of neuronal cells but also participates in the pathogenesis of various neuropsychological diseases.In this study,we reported increased NO production in CHME-5 microglia cells after they were transfected with HERV-W env.Moreover,HERV-W env increased the expression and function of human inducible nitric oxide synthase (hiNOS) and enhanced the promoter activity of hiNOS.Microglial migration was also enhanced.These data revealed that HERV-W env might contribute to increase NO production and microglial migration ability in neuropsychological disorders by regulating the expression of inducible NOS.Results from this study might lead to the identification of novel targets for the treatment of neuropsychological diseases,including neuroinflammatory diseases,stroke,and neurodegenerative diseases.

  • 加载中
    1. Adachi R, Matsui S, Kinoshita M, Nagaishi K, Sasaki H, Kasahara T, Suzuki K. 2000. Nitric oxide induces chemotaxis of neutrophil-like HL-60 cells and translocation of cofilin to plasma membranes. Int J Immunopharmacol, 22: 855–864.
        doi: 10.1016/S0192-0561(00)00045-X

    2. Alderton WK, Cooper CE, Knowles RG. 2001. Nitric oxide synthases: structure, function and inhibition. Biochem J, 357: 593–615.
        doi: 10.1042/bj3570593

    3. Antony JM, Ellestad KK, Hammond R, Imaizumi K, Mallet F, Warren KG, Power C. 2007. The human endogenous retrovirus envelope glycoprotein, syncytin-1, regulates neuroinflammation and its receptor expression in multiple sclerosis: a role for endoplasmic reticulum chaperones in astrocytes. J Immunol, 179: 1210–1224.
        doi: 10.4049/jimmunol.179.2.1210

    4. Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, Wallace JL, Deacon RM, Warren K, Power C. 2004. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nature Neuroscience, 7:1088–1095.
        doi: 10.1038/nn1319

    5. Asiimwe N, Yeo SG, Kim MS, Jung J, Jeong NY. 2016. Nitric Oxide: Exploring the Contextual Link with Alzheimer’s Disease. Oxid Med Cell Longev, 2016: 7205747.

    6. Bao J, Zhu J, Luo S, Cheng Y, Zhou S. 2016. CXCR7 suppression modulates microglial chemotaxis to ameliorate experimentally-induced autoimmune encephalomyelitis. Biochemical and Biophysical Research Communications, 469: 1–7.
        doi: 10.1016/j.bbrc.2015.11.059

    7. Bjerregaard B, Holck S, Christensen IJ, Larsson LI. 2006. Syncytin is involved in breast cancer-endothelial cell fusions. Cell Mol Life Sci, 63: 1906–1911.
        doi: 10.1007/s00018-006-6201-9

    8. Brodsky I, Foley B, Gillespie D. 1993. Expression of human endogenous retrovirus (HERV-K) in chronic myeloid leukemia. Leuk Lymphoma, 11 Suppl 1: 119–123.

    9. Clausen J. 2003. Endogenous retroviruses and MS: using ERVs as disease markers. Int MS J, 10: 22–28.

    10. Colton CA. 2009. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol, 4: 399–418.
        doi: 10.1007/s11481-009-9164-4

    11. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. 1997. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell, 90: 303–313.
        doi: 10.1016/S0092-8674(00)80338-4

    12. Czeh M, Gressens P, Kaindl AM. 2011. The yin and yang of microglia. Dev Neurosci, 33: 199–209.
        doi: 10.1159/000328989

    13. de Vera ME, Shapiro RA, Nussler AK, Mudgett JS, Simmons RL, Morris SJ, Billiar TR, Geller DA. 1996. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci U S A, 93: 1054–1059.
        doi: 10.1073/pnas.93.3.1054

    14. Draheim HJ, Prinz M, Weber JR, Weiser T, Kettenmann H, Hanisch UK. 1999. Induction of potassium channels in mouse brain microglia: cells acquire responsiveness to pneumococcal cell wall components during late development. Neuroscience, 89: 1379–1390.
        doi: 10.1016/S0306-4522(98)00407-2

    15. Dzoljic E, Grbatinic I, Kostic V. 2015. Why is nitric oxide important for our brain? Funct Neurol, 30: 159–163.

    16. Frendo JL, Olivier D, Cheynet V, Blond JL, Bouton O, Vidaud M, Rabreau M, Evain-Brion D, Mallet F. 2003. Direct involvement of HERV-W Env glycoprotein in human trophoblast cell fusion and differentiation. Mol Cell Biol, 23: 3566–3574.
        doi: 10.1128/MCB.23.10.3566-3574.2003

    17. Fuseler JW, Valarmathi MT. 2016. Nitric Oxide Modulates Postnatal Bone Marrow-Derived Mesenchymal Stem Cell Migration. Front Cell Dev Biol, 4: 133.

    18. Galea E, Feinstein DL, Reis DJ. 1992. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc Natl Acad Sci U S A, 89: 10945–10949.
        doi: 10.1073/pnas.89.22.10945

    19. Ghasemi M, Fatemi A. 2014. Pathologic role of glial nitric oxide in adult and pediatric neuroinflammatory diseases. Neuroscience & Biobehavioral Reviews, 45: 168–182.

    20. Gimenez J, Montgiraud C, Pichon JP, Bonnaud B, Arsac M, Ruel K, Bouton O, Mallet F. 2010. Custom human endogenous retroviruses dedicated microarray identifies self-induced HERV-W family elements reactivated in testicular cancer upon methylation control. Nucleic Acids Res, 38: 2229–2246.
        doi: 10.1093/nar/gkp1214

    21. Hanisch UK, Kettenmann H. 2007. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci, 10: 1387–1394.
        doi: 10.1038/nn1997

    22. Huang W, Li S, Hu Y, Yu H, Luo F, Zhang Q, Zhu F. 2011. Implication of the env gene of the human endogenous retrovirus W family in the expression of BDNF and DRD3 and development of recent-onset schizophrenia. Schizophrenia Bulletin, 37: 988–1000.
        doi: 10.1093/schbul/sbp166

    23. Huang W, Liu Z, Wei W, Wang G, Wu J, Zhu F. 2006. Human endogenous retroviral pol RNA and protein detected and identified in the blood of individuals with schizophrenia. Schizophrenia Research, 83: 193–199.
        doi: 10.1016/j.schres.2006.01.007

    24. Jaffrey SR, Snyder SH. 1995. Nitric oxide: a neural messenger. Annu Rev Cell Dev Biol, 11: 417–440.
        doi: 10.1146/annurev.cb.11.110195.002221

    25. Janabi N, Peudenier S, Heron B, Ng KH, Tardieu M. 1995. Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen. Neurosci Lett, 195: 105–108.
        doi: 10.1016/0304-3940(94)11792-H

    26. Jern P, Sperber GO, Blomberg J. 2004. Definition and variation of human endogenous retrovirus H. Virology, 327: 93–110.
        doi: 10.1016/j.virol.2004.06.023

    27. Karlsson H, Schroder J, Bachmann S, Bottmer C, Yolken RH. 2004. HERV-W-related RNA detected in plasma from individuals with recent-onset schizophrenia or schizoaffective disorder. Mol Psychiatry, 9: 12–13.
        doi: 10.1038/

    28. Klegeris A, McGeer EG, McGeer PL. 2007. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol, 20: 351–357.
        doi: 10.1097/WCO.0b013e3280adc943

    29. Ko HM, Kim SY, Joo SH, Yang SI, Shin CY, Koo BN. 2013. Synergistic activation of lipopolsaccharide-stimulated glial cells by propofol. Biochem Biophys Res Commun, 438:420–426.
        doi: 10.1016/j.bbrc.2013.07.089

    30. Kumar S, Singh RK, Bhardwaj TR. 2017. Therapeutic role of nitric oxide as emerging molecule. Biomedicine & Pharmacotherapy, 85: 182–201.
        doi: 10.1016/j.biopha.2016.11.125

    31. Lefer AM, Lefer DJ. 1999. Nitric oxide. II. Nitric oxide protects in intestinal inflammation. Am J Physiol, 276: G572–G575.

    32. Li S, Liu ZC, Yin SJ, Chen YT, Yu HL, Zeng J, Zhang Q, Zhu F. 2013. Human endogenous retrovirus W family envelope gene activates the small conductance Ca2+-activated K+ channel in human neuroblastoma cells through CREB. Neuroscience, 247: 164–174.
        doi: 10.1016/j.neuroscience.2013.05.033

    33. Li H, Liu B, Huang J, Chen H, Guo X, Yuan Z. 2013. Insulin inhibits lipopolysaccharide-induced nitric oxide synthase expression in rat primary astrocytes. Brain Res, 1506:1–11.
        doi: 10.1016/j.brainres.2013.01.055

    34. Li W, Yang F, Liu Y, Gong R, Liu L, Feng Y, Hu P, Sun W, Hao Q, Kang L, Wu J, Zhu Y. 2009. Negative feedback regulation of IL-32 production by iNOS activation in response to dsRNA or influenza virus infection. European Journal of Immunology, 39: 1019–1024.
        doi: 10.1002/eji.v39:4

    35. Lu A, Wang L, Qian L. 2015. The role of eNOS in the migration and proliferation of bone-marrow derived endothelial progenitor cells and in vitro angiogenesis. Cell Biol Int, 39: 484–490.
        doi: 10.1002/cbin.v39.4

    36. Maeda T, Inagaki M, Fujita Y, Kimoto T, Tanabe-Fujimura C, Zou K, Liu J, Liu S, Komano H. 2016. ATP increases the migration of microglia across the brain endothelial cell monolayer. Biosci Rep, 36: e00318.
        doi: 10.1042/BSR20160054

    37. Mallet F, Bouton O, Prudhomme S, Cheynet V, Oriol G, Bonnaud B, Lucotte G, Duret L, Mandrand B. 2004. The endogenous retroviral locus ERVWE1 is a bona fide gene involved in hominoid placental physiology. Proc Natl Acad Sci U S A, 101: 1731–1736.
        doi: 10.1073/pnas.0305763101

    38. Mameli G, Astone V, Arru G, Marconi S, Lovato L, Serra C, Sotgiu S, Bonetti B, Dolei A. 2007. Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6. Journal of General Virology, 88:264–274.
        doi: 10.1099/vir.0.81890-0

    39. Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, LaVallie E, Tang XY, Edouard P, Howes S, Keith JJ, McCoy JM. 2000. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature, 403: 785–789.
        doi: 10.1038/35001608

    40. Moussaud S, Lamodiere E, Savage C, Draheim HJ. 2009. Characterisation of K+ currents in the C8-B4 microglial cell line and their regulation by microglia activating stimuli. Cell Physiol Biochem, 24: 141–152.
        doi: 10.1159/000233240

    41. Mustafa AK, Gadalla MM, Snyder SH. 2009. Signaling by gasotransmitters. Sci Signal, 2:e2.

    42. Nakagawa K, Brusic V, McColl G, Harrison LC. 1997. Direct evidence for the expression of multiple endogenous retroviruses in the synovial compartment in rheumatoid arthritis. Arthritis Rheum, 40: 627–638.
        doi: 10.1002/(ISSN)1529-0131

    43. Nakamura T, Cho DH, Lipton SA. 2012. Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol, 238: 12–21.
        doi: 10.1016/j.expneurol.2012.06.032

    44. Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, Mallet F, Tuke PW, Voisset C, Blond JL, Lalande B, Seigneurin JM, Mandrand B. 1997. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A, 94: 7583–7588.

    45. Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP. 2012. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler, 18: 1721–1736.
        doi: 10.1177/1352458512441381

    46. Perron H, Lazarini F, Ruprecht K, Pechoux-Longin C, Seilhean D, Sazdovitch V, Creange A, Battail-Poirot N, Sibai G, Santoro L, Jolivet M, Darlix JL, Rieckmann P, Arzberger T, Hauw JJ, Lassmann H. 2005. Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol, 11: 23–33.

    47. Qin C, Li S, Yan Q, Wang X, Chen Y, Zhou P, Lu M, Zhu F. 2016. Elevation of Ser9 phosphorylation of GSK3β is required for HERV-W env-mediated BDNF signaling in human U251 cells. Neuroscience Letters, 627: 84–91.
        doi: 10.1016/j.neulet.2016.05.036

    48. Saha RN, Pahan K. 2006. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal, 8: 929–947.
        doi: 10.1089/ars.2006.8.929

    49. Saha RN, Pahan K. 2006b. Signals for the induction of nitric oxide synthase in astrocytes. Neurochem Int, 49:154–163.
        doi: 10.1016/j.neuint.2006.04.007

    50. Sang J, Chen Y, Tao Y. 2011. Nitric oxide inhibits gastric cancer cell growth through the modulation of the Akt pathway. Mol Med Rep, 4: 1163–1167.

    51. Scheiblich H, Roloff F, Singh V, Stangel M, Stern M, Bicker G. 2014. Nitric oxide/cyclic GMP signaling regulates motility of a microglial cell line and primary microglia in vitro. Brain Res, 1564: 9–21.
        doi: 10.1016/j.brainres.2014.03.048

    52. Seifarth W, Baust C, Murr A, Skladny H, Krieg-Schneider F, Blusch J, Werner T, Hehlmann R, Leib-Mosch C. 1998. Proviral structure, chromosomal location, and expression of HERV-K-T47D, a novel human endogenous retrovirus derived from T47D particles. J Virol, 72: 8384–8391.

    53. Shaikh SB, Uy B, Perera A, Nicholson LFB. 2012. AGEs–RAGE mediated up-regulation of connexin43 in activated human microglial CHME-5 cells. Neurochemistry International, 60: 640–651.
        doi: 10.1016/j.neuint.2012.02.023

    54. Wallace JL. 2005. Nitric oxide as a regulator of inflammatory processes. Mem Inst Oswaldo Cruz, 100 Suppl 1: 5–9.

    55. Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, Rosen DG, Chen DT, Lu DW, Barnhart KF, Johanning GL. 2007. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer, 120: 81–90.
        doi: 10.1002/(ISSN)1097-0215

    56. Yolken RH, Torrey EF. 1995. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev, 8: 131–145.

    57. Yu H, Liu T, Zhao Z, Chen Y, Zeng J, Liu S, Zhu F. 2014. Mutations in 3’-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb. Oncogene, 33: 3947–3958.
        doi: 10.1038/onc.2013.366

    58. Yun HY, Dawson VL, Dawson TM. 1997. Nitric oxide in health and disease of the nervous system. Mol Psychiatry, 2: 300–310.
        doi: 10.1038/

    59. Zhang Z, Cao Z, Liu C, Li R, Wang W, Wang X. 2016. MiRNA-Embedded ShRNAs for Radiation-Inducible LGMN Knockdown and the Antitumor Effects on Breast Cancer. PLOS ONE, 11:e163446.

    60. Zhou L, Zhang H, Wu J. 2016. Effects of nitric oxide on the biological behavior of HepG2 human hepatocellular carcinoma cells. Exp Ther Med, 11: 1875–1880.

    61. Zhou Y, Zhao Y, Gao Y, Hu W, Qu Y, Lou N, Zhu Y, Zhang X, Yang H. 2017. Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation. J Exp Clin Cancer Res, 36:42.
        doi: 10.1186/s13046-017-0510-8

    62. Zhu T, Yao Q, Wang W, Yao H, Chao J. 2016. iNOS Induces Vascular Endothelial Cell Migration and Apoptosis Via Autophagy in Ischemia/Reperfusion Injury. Cell Physiol Biochem, 38: 1575–1588.
        doi: 10.1159/000443098

    63. Zipp F, Aktas O. 2006. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci, 29: 518–527.
        doi: 10.1016/j.tins.2006.07.006

    64. Zou F, Liu Y, Liu L, Wu K, Wei W, Zhu Y, Wu J. 2007. Retinoic acid activates human inducible nitric oxide synthase gene through binding of RARα/RXRα heterodimer to a novel retinoic acid response element in the promoter. Biochemical and Biophysical Research Communications, 355: 494–500.
        doi: 10.1016/j.bbrc.2007.01.178

  • 加载中


Article Metrics

Article views(7130) PDF downloads(20) Cited by()

Proportional views

    Human endogenous retrovirus W env increases nitric oxide production and enhances the migration ability of microglia by regulating the expression of inducible nitric oxide synthase

      Corresponding author: Fan Zhu,
    • 1. Department of Medical Microbiology, School of Medicine, Wuhan University, Wuhan 430071, China
    • 2. Department of Integrated Medicine, Dongfeng Hospital, Hubei University of Medicine, Wuhan 442000, China
    • 3. Department of Neurology Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China
    • 4. The State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China
    • 5. Hubei Province Key Laboratory of Allergy and Immunology, Wuhan 430071, China

    Abstract: Human endogenous retrovirus W env (HERV-W env) plays a critical role in many neuropsychological diseases such as schizophrenia and multiple sclerosis (MS).These diseases are accompanied by immunological reactions in the central nervous system (CNS).Microglia are important immunocytes in brain inflammation that can produce a gasotransmitter-nitric oxide (NO).NO not only plays a role in the function of neuronal cells but also participates in the pathogenesis of various neuropsychological diseases.In this study,we reported increased NO production in CHME-5 microglia cells after they were transfected with HERV-W env.Moreover,HERV-W env increased the expression and function of human inducible nitric oxide synthase (hiNOS) and enhanced the promoter activity of hiNOS.Microglial migration was also enhanced.These data revealed that HERV-W env might contribute to increase NO production and microglial migration ability in neuropsychological disorders by regulating the expression of inducible NOS.Results from this study might lead to the identification of novel targets for the treatment of neuropsychological diseases,including neuroinflammatory diseases,stroke,and neurodegenerative diseases.

      • Human endogenous retrovirus (HERV) is reported to account for about 8% of the human genome, and its sequence is highly conserved (Jern et al., 2004). HERV-W is a typical representative of the HERV family. A single complete open reading frame (ORF) that putatively encodes the HERV-W envelope (env) is located on human chromosome 7 and can be transcribed and translated into the envelope protein syncytin-1 (Frendo et al., 2003). HERV-W env is not only highly expressed in the placenta but also has fusogenic properties evident in normal trophoblast development in healthy humans (Mallet et al., 2004). However, many more studies have shown that HERV-W env contributes to neuropsychological diseases, including schizophrenia (Karlsson et al., 2004; Huang et al., 2006; Huang et al., 2011), Alzheimer’s disease (AD) (Nakamura et al., 2012), and multiple sclerosis (MS) (Perron et al., 2005; Perron et al., 2012; Perron et al., 1997). Furthermore, these diseases may be associated with brain inflammation (Zipp et al., 2006).

        Although the brain is considered an “immunologically privileged site”, mainly because of the blood-brain barrier (BBB), immunological reactions can occur in the CNS. Brain inflammation has been implicated in the pathology of neuropsychological diseases such as stroke, Parkinson’s disease (PD), and human immunodefi- ciency virus-associated dementia (Klegeris et al., 2007; Nakamura et al., 2012; Zipp et al., 2006). In addition, microglia are recognized as immunocytes in the CNS, and their function is to protect the brain from pathogenic bacteria and viruses, and the inflammatory response to these microorganisms (Maeda et al., 2016). A number of studies have shown cellular migration in CNS (Bao et al., 2016). After CNS damage, microglia at the lesion will enter pro-inflammatory (Draheim et al., 1999; Moussaud et al., 2009) and anti-inflammatory (Czeh et al., 2011; Hanisch et al., 2007) sites to promote repair neurocytes proliferation and migration. Microglia, a type of glial cell, produce two subtypes of identified nitric oxide synthase (NOS); one is a constitutive neuronal NOS (nNOS) and the other one is an inducible NOS (iNOS), which promotes the production of additional NO in response to various stimuli (Ghasemi et al., 2014; Li et al., 2009). NO, a free radical molecule, is synthesized from L-arginine by NOS in many mammalian cells and tissues, especially in the brain. At lower concentrations (pmol), nNOS-derived NO exerts beneficial effects on the body by playing vital roles such as antibacterial and antiviral activities (Ghasemi et al., 2014; Kumar et al., 2017). At higher concentrations (μmol), iNOS-derived NO is involved in the pathogenesis of various neuropsychological diseases, including neuroinflammatory diseases, schizophrenia, epilepsy, neurodegenerative diseases, and stroke (Kumar et al., 2017).

        Numerous factors have been associated with neuropsychiatric disorders; however, the cause of these diseases remains unclear (Yolken et al., 1995). As discussed above, both HERV-W env and NO contribute to the pathogenesis of neurological disorders such as MS, AS, and schizophrenia (Asiimwe et al., 2016; Ghasemi et al., 2014). Through immunohistochemistry, microglia have been shown to express HERV-W env (Mameli et al., 2007; Antony et al., 2004). However, questions remain: is there an association between HERV-W env and changes in NO levels in microglia in the CNS, and what factors directly lead to changes in NO levels? Answers to these questions have not been reported in the literature.

        In this study, by measuring the expression of iNOS and changes in microglia migration, we showed that overexpression of HERV-W env promoted inflammation in microglia. Results of this study can suggest new approaches to therapeutic interventions for neuropsychological diseases.

      • pCMV-env was constructed in a previous study (Huang et al., 2011). Luciferase reporter gene plasmids containing iNOS promoters 8 kb, 7 kb, 6 kb, 4 kb, 3 kb, 2 kb, and 1 kb in length were given as gifts by Professor Ying Zhu, Wuhan University, China (Zou et al., 2007).

      • A common human microglia cell line, CHME-5, given as a gift by Professor Wenzhe Huo (Department of Anatomy and Molecular Biology, Temple University, USA), were cultured in Dulbecco’s modified Eagle’s medium (Gibco BRL) supplemented with 10% fetal bovine serum (Gibco BRL), 2 mmol/L GlutaMAX (Gibco BRL), 10 mmol/L MEM non-essential amino acids (Invitrogen), 100 U/mL penicillin, and 0.1 mg/mL streptomycin at 37 °C in a humidified 5% CO2 incubator (Janabi et al., 1995; Shaikh et al., 2012). Transfection was performed in complete medium without antibiotics when the density of cells was about 70%. The plasmids were transfected into cells using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Cells were collected after transfection for 24 h or 48 h. Cell culture supernatants were collected at 6, 12, 24, and 48 h after transfection and immediately stored at –70 °C until use.

      • NO production was indirectly quantified by measuring nitrite levels using a NO Detection Assay Kit (Beyotime, China). A standard curve of nitrite was established, and nitrite in each sample was assessed by mixing 50 μL of culture supernatant with 50 μL of Griess reagent I/II in a 96-well plate. Plates were gently shaken and held at 20 °C for 10 min, and the absorbances at 540 nm were recorded. Nitrite concentrations in the samples were compared with the nitrite standard curve, with nitrite concentrations ranging from 0 to 100 μmol/L.

      • Total RNA was extracted with TRIzol reagent (Invitrogen) from cells and treated with DNase I (Promega, Madison, WI) according to the manufacturer’s protocol. After RNA extraction, cDNA was obtained using a Clontech SMART PCR cDNA Library Construction Kit (Clontech, Palo Alto, CA). Quantitative real-time PCR was performed using DNA SYBR Green PCR Master Mix (Molecular Probes, Eugene, OR, USA) in an iCycler System (Bio-Rad, Hercules, CA, USA), and results were normalized to β-actin levels. Sequences of primers used in real-time quantitative PCR are listed below: iNOS sense, 5′-CAAAGGCTGTGAGTCCTGCAC-3′; iNOS antisense, 5′-ACTTTGATCAGAAGCTGTCCC-3′ (Antony et al., 2007); HERV-W env sense, 5′-CCATGCCGCTGTATGACCAG-3′; HERV-W env antisense, 5′-GGGTTCCCTTAGAAAGACTCCT-3′; β-actin sense, 5′-CATGTACGTTGCTATCCAGGC-3′; and β-actin antisense, 5′-CTCCTTAATGTCACGCACGAT-3′ (Yu et al., 2014).

      • Cells were washed twice with PBS on ice and lysed by adding lysis buffer (Pierce Chemical, Rockford, IL, USA). Supernatants were collected after centrifugation at 14,000 g for 10 min at 4 °C. Protein concentrations were determined using a BCA Protein Assay Kit. For each sample, 40 μg of total protein was separated by 8% SDS-PAGE. Western blotting was performed using rabbit anti-human iNOS antibody (ab3523, Abcam) at a dilution of 1:200. Polyclonal goat anti-rabbit IgG horseradish peroxidase (HRP)-conjugated antibody (cw0103s, CWBiotech) was used as the secondary antibody at a dilution of 1:5000. β-actin (SAB2701711, Sigma-Aldrich), at a concentration of 1:30,000, was used as a control.

      • iNOS activity was detected using a Nitric Oxide Synthase Assay Kit (Beyotime, China) according to the manufacturer’s instructions. S-methylisothiourea sulfate (SMT) (Beyotime, China), a highly selective inhibitor of iNOS, was dissolved in NO synthase detection buffer (1×) for a final concentration of 100 mmol/L. After 24 h of transfection, CHME-5 cells were gently digested with trypsin (0.25% EDTA-trypsin: 1× D-hanks solution = 1: 4) for 2 min and washed with ice-cold PBS three times. The fluorescence intensity of DAF-FM DA, a fluorescent probe for NO, was measured by flow cytometry (FACS Aria III, BD) at excitation and emission wavelengths of 495 nm and 515 nm, respectively. Results are expressed in relative fluorescence activity units (RFUs).

      • Luciferase activities were measured using a Dual Luciferase Reporter Gene Assay Kit (Beyotime, China) according to the manufacturer’s instructions. Twenty-four hours after co-transfection with luciferase reporter plasmids and pCMV or pCMV-env, CHME-5 cells were washed two times using 1× PBS and lysed by cell lysis buffer for 10 min. Firefly luciferase and Renilla luciferase activities were detected, and the latter, an internal control, was used to eliminate the impact of cell number and transfection efficiency. Results are expressed in relative luciferase activity units (RLUs).

      • Migration of the transfected cells was measured by Transwell assay according to the manufacturer’s protocol. For the cell migration assay, cells were diluted to 1.0 × 105/mL and cultured in 100 μL of cell suspension without fetal bovine serum (FBS) in the upper chamber, and 600 μL of culture medium with 10% FBS was used to create an osmotic pressure difference to promote cell migration to the lower chamber of the Transwell insert (Corning). After 12 h of culture in a 37 °C incubator, the cells that did not migrate were removed with a cotton swab. Migrating cells were fixed with 90% ethanol for 15 min and then stained with crystal violet for 20 min. Then, the migrated cells in at least four fields were observed and counted under a high magnification (400×) inverted microscope. A wound healing assay was also performed. Procedures for the assay are described elsewhere in detail (Zhou et al., 2017; Zhang et al., 2016).

      • Each group of experiments was replicated at least three times. A histogram shows the results of the statistical analyses. Result of the experiments were evaluated by Student’s t test or F test (one-way ANOVA), and P values less than 0.05 were considered statistically significant. P less than 0.01 indicated a significant difference.

      • Microglia, immunocytes in the CNS, produce inflammatory molecules, namely NO, after stimulation (Colton, 2009). We determined the effects of HERV-W env on NO production using a NO Detection Assay Kit. HERV-W env expression was increased 3.06 fold and 1.65 fold at the mRNA and protein levels, respectively (P < 0.05, Figure 1A). A standard curve was constructed (Figure 1B). NO content increased 1.68 fold (P > 0.05), 2.52 fold (P < 0.05), 3.07 fold (P < 0.01), and 2.21 fold (P < 0.05) at 6 h, 12 h, 24 h, and 48 h, respectively, after transfection with pCMV-env. As shown in Figure 1C, NO accumulated in microglia in a time-dependent manner after overexpression.

        Figure 1.  HERV-W env increased NO in microglia in a time-dependent manner.

      • NO is synthesized in the brain from two kinds of NOS (Kumar et al., 2017). To verify whether the increase in NO was caused by an increase in iNOS expression, real-time PCR and western blotting were used to examine iNOS expression. iNOS mRNA increased 2.55 fold in CHME-5 cells, as determined by real-time PCR (Figure 2A, P < 0.01). iNOS protein was evaluated by western blotting and was found to increase by 52.9% after transfection of CHME-5 cells with HERV-W env (Figure 2B2C, P < 0.05). Taken together, these results indicate that HERV-W env increases expression of both iNOS mRNA and protein in microglia.

        Figure 2.  HERV-W env increased iNOS expression in microglia.

      • To further define the relationship between iNOS activity and HERV-W env expression, we determined the effects of HERV-W env on iNOS activity using a Nitric Oxide Synthase Assay Kit. The role of HERV-W env was confirmed by flow cytometric analysis; the fluores- cence intensity of DAF-FM DA of different groups was determined (Figure 3A3F). As shown in Figure 3G, fluorescence intensity increased by 73% without SMT compared to with pCMV (P < 0.001), and RFU decreased by 7.1% (P > 0.05), 18% (P < 0.05), and 49% (P < 0.001) with different concentrations of SMT. These data strongly supported the idea that HERV-W env overexpression induces the activation of iNOS in microglia.

        Figure 3.  HERV-W env overexpression activated iNOS in microglia.

      • The iNOS promoter plays important roles in its expression (Ghasemi et al., 2014). To examine whether HERV-W env had an effect on iNOS promoter activity, cells were transiently transfected with the iNOS promoter/luciferase reporter, with or without overexpression of HERV-W env. The truncated promoters were missing segments at the 5′-terminus (Figure 4A). As shown in Figure 4B, iNOS promoter activity increased after HERV-W env transfection, with approximately 1.69-fold (P < 0.01), 1.71-fold (P < 0.01), 1.22-fold (P < 0.05), 1.25-fold (P < 0.05), and 1.44-fold (P < 0.05) increases in iNOS promoter activity observed after transfection with plasmids containing promoters 8 kb, 7 kb, 6 kb, 4 kb, and 3 kb in length, respectively. However, the 2-kb (P > 0.05) and 1-kb (P > 0.05) promoters had no significant effect on iNOS promoter activity. These results suggested that HERV-W env enhanced iNOS activation in microglia and that the 3-kb sequence of the 3′ terminus of the full-length promoter was the minimum sequence required.

        Figure 4.  HERV-W env expression enhanced iNOS promoter activation.

      • Microglia migrate after stimulation such as brain injury and immunological reactions (Zhu et al., 2016). NO is a primary cause for cellular migration, and HERV-W env was previously found to increase NO. Therefore, we speculated that HERV-W env might lead to migration of microglia. To confirm the relationship between HERV-W env overexpression and microglia migration, after transfection with pCMV-env for 24 h, CHME-5 cells were transferred into a transwell chamber and cultured for another 12 h. Results showed that the number of migrated cell numbers increased after transfection with pCMV-env. The number of migrating cells with the blank vector control (pCMV) and expression vector (pCMV-env) was 10 ± 2 (means ± SME, Figure 5A) and 47 ± 2 (Figure 5B), respectively. The number of migrating cells following HERV-W env activation increased 4.7 fold (Figure 5C, P < 0.001). These data showed that overexpression of HERV-W env enhanced the migration of microglia. Moreover, results from the wound healing assay showed that the mobility of microglia increased 1.93 fold after transfection with pCMV-env (Figure 5D). These results confirmed that HERV-W env overexpression enhanced the migration of microglia.

        Figure 5.  HERV-W env enhanced the migration of microglia.

        In conclusion, HERV-W env overexpression resulted in an increase in NO over time and upregulated the expression, function, and promoter activity of iNOS, thereby increasing the migration of microglia. These results suggest that HERV-W env expression is associated with inflammation of microglia.

      • Many copies of endogenous retroviral elements integrate into the human genome, representing about 8% of the human genome (Jern et al., 2004). Most sequences are defective (Brodsky et al., 1993). A minority of sequences are full-length copies of retroviruses (Brodsky et al., 1993) which may have the potential to be packaged into complete viral particles in the human body (Seifarth et al., 1998). HERV-W, an endogenous retroviral element, has a typical HERV structure, which is: 5′-LTR-gap-(pro)-pol-env-3′-LTR. HERV-W env is expressed in human placenta (Mi et al., 2000) and facilitates cell-cell fusion during trophoblast development (Frendo et al., 2003; Mallet et al., 2004). However, HERV-W env also contributes to various diseases, including schizophrenia (Karlsson et al., 2004), MS (Clausen, 2003), rheumatoid arthritis (Nakagawa et al., 1997), diabetes mellitus (Conrad et al., 1997), and several types of cancer (Bjerregaard et al., 2006; Gimenez et al., 2010; Wang-Johanning et al., 2007; Yu et al., 2014). These diseases are associated with inflammatory reactions. Therefore, there is a possibility that HERV-W env is activated in response to host immunity.

        Because the BBB normally restricts the passage of immunocytes from the blood into the brain, the brain has been considered an "immunologically privileged site." However, immunological reactions, especially brain inflammation, occur in the CNS. NO produced by microglia plays a major role in brain inflammation. NO participates in the suppression of neutrophil adhesion and migration in acute inflammation (Adachi et al., 2000; Lefer et al., 1999).

        On one hand, NO is a signaling molecule in the CNS, and, at appropriate levels, it maintains a dynamic balance (Kumar et al., 2017). On the other hand, NO freely diffusing across cellular membranes plays an essential role as a neurotransmitter in the CNS, unlike other classical neurotransmitters (Asiimwe et al., 2016). For example, NO directly modifies intracellular targets in neurotransmitter signaling pathways by crossing cellular membranes through passive transport (Mustafa et al., 2009). NO has been found to modulate physiological responses in diseases in three ways: a. stimulating host immune defenses, b. regulating neural transmissions in the brain, and c. enhancing inflammation (Jaffrey et al., 1995). A previous study implicates NO produced by microglia in the pathophysiology of a wide variety of neuropsychological diseases such as MS and AD (Scheiblich et al., 2014; Yun et al., 1997). In this study, we examined changes in NO levels when HERV-W env was overexpressed in microglia. HERV-W env was found to trigger a time-dependent increase in NO levels (Figure 1).

        NO is synthesized in the body from three kinds of NOS (Kumar et al., 2017). The release of endothelial NOS (eNOS)-derived NO occurs in response to vascular permeability and angiogenesis in chronic inflammation (Wallace, 2005). NO can act as a “double-edged sword, ” which might be exploited to develop therapies for neuropsychological disorders (Dzoljic et al., 2015). iNOS, the third isoform, is induced by acute inflammation (Alderton et al., 2001). Microglia do not express iNOS in a normal physiological state, but they an express iNOS with pathologies such as inflammatory injury (Galea et al., 1992). In this study, we showed that HERV-W env upregulated iNOS expression (Figure 2). Based on previous experiments, we speculated that increased NO was a result of elevated iNOS expression. The release of high amounts of NO synthesized from iNOS is responsible for the adverse effects of NO in inflammatory sites.

        Specific enzymatic activity, namely iNOS activity, is induced by stimuli and plays an important role in inflammation. Total enzymatic activity, which includes iNOS activity, has biological effects in the body. Isothiourea analogues inhibit iNOS activity by competing for iNOS binding sites on L-arginine. SMT is an isothiourea analogue. As a non-acid L-arginine analogue, SMT is a powerful and specific selective inhibitor of iNOS in humans (Alderton et al., 2001). In this study, SMT was used to inhibit iNOS to determine whether increased NO production resulted from an increase in iNOS activity. HERV-W env was found to enhance the activity of iNOS (Figure 3). Such isothiourea analogues can be employed to study of NOS isoenzymes and iNOS changes in various pathophysiological conditions.

        The iNOS promoter plays an important role in regulating iNOS expression. Recently, HERV-W env expression has been proposed to increase the activation of promoters of some genes and to enhance expression of these genes in individuals such as those with schizophrenia (Huang et al., 2011; Li et al., 2013; Qin et al., 2016). Functional promoter elements of hiNOS are located upstream of the 3.8-kb and 7.2-kb promoter regions of the hiNOS gene when induced by cytokines (de Vera et al., 1996). In addition, although hiNOS uses the same cytokines to regulate transcription, hiNOS utilizes different models of gene regulation in human glial cells (Saha et al., 2006a). Thus, we examined the activity of the iNOS promoter by co-transfection with reporter plasmids and pCMV-env (Figure 4). Results showed that HERV-W env enhanced iNOS promoter activity and that the truncated 3-kb promoter sequence was necessary. Moreover, the functional and necessary promoter element that controlled hiNOS expression induced by HERV-W env was found upstream of the 3.1-kb promoter region of the iNOS gene in humans. NF-κB and MAPK signaling were found to regulate iNOS expression by regulating the activity of the hiNOS promoter. LPS mainly induces iNOS expression through the classical NF-κB pathway, whereas expression through the MAPK pathway has been identified in neuropsychological disorders (Ko et al., 2013; Li et al., 2013; Saha et al., 2006b). Therefore, we speculated that HERV-W env could affect hiNOS promoter activity through the classical NF-κB pathway and/or MAPK signaling pathway.

        NO, an inflammatory molecule, promotes immunocytes to migrate to lesions by dispersing through the microenvironment. NO either stimulates or inhibits cellular migration, depending on the conditions, tissue location, and types of cells present (Fuseler et al., 2016). NO has been shown to be either a requirement or a stimulus for cellular migration. Studies have shown that NO can increase the migration of microglia cells (BV-2) and umbilical vein endothelial cells (HUVECs), and that iNOS inhibitor suppresses the migration of these cells (Scheiblich et al., 2014; Zhu et al., 2016). However, NO also inhibits the migration of tumor cells such as HepG2 and gastric cancer cells (Sang et al., 2011; Zhou et al., 2016). Therefore, NO has highly variable effects on cell migration and its presence is required for various cellular functions (Lu et al., 2015). We assessed microglia migration using Transwell and wound healing assays when HERV-W env was overexpressed (Figure 5). The results showed that NO increased with overexpression of HERV-W env, enhancing the capacity of microglial CHME-5 cells to migrate.

        In this study, the data indicated that activating the expression of HERV-W env affected inflammation by causing NO to accumulate, leading to the expression of iNOS, upregulating iNOS promoter activity, and facilitating migration of microglia. In conclusion, we found that HERV-W env overexpression was associated with iNOS-derived NO overproduction in microglia and promoted inflammation of microglia. The expression of iNOS contributes to the pathogenesis of the neuropsychological disorders. Our study suggests therapeutic approaches based on reducing NO overproduction to attenuate neuropsychological diseases such as schizophrenia and MS.

      • This work was supported by grants from the National Natural Sciences Foundation of China (No. 31470264, No. 81271820, No. 30870789, and No. 30300117), the Key Program of Natural Science Foundation of Hubei Province of China (No. 2014CFA078), the Stanley Foundation from the Stanley Medical Research Institute (SMRI), USA (No. 06R-1366), to Dr. Fan Zhu and the Scientific Innovation Team Project of Hubei Province of China (No. 2015CFA009).

      • The authors declare that they have no conflicts of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.

      • FZ conceived the experiments. RX, SL, XLW, QJY, and XNT carried out the experiments. RX and QC analyzed the data. YZ contributed materials and provided luciferase reporter gene plasmids containing the iNOS promoter. RX prepared the figures and/or tables and drafted the manuscript. FZ finalized the manuscript. All authors read and approved the final manuscript.

    Figure (5)  Reference (64) Relative (20)



    DownLoad:  Full-Size Img  PowerPoint